De Novo Pathway Demystified: When to Use It and How to Prepare for FDA Success

What the De Novo Pathway Actually Is—and Why It Matters

If your medical device is genuinely novel—meaning there is no legally marketed predicate device to support a 510(k)—but it also does not pose the level of risk that would require a full Premarket Approval (PMA), you are not in a regulatory dead end. You are a candidate for the De Novo pathway.

Established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and codified through FDA's implementing regulations, the De Novo process allows FDA to classify novel, low-to-moderate risk devices into Class I or Class II—creating a new regulatory classification that did not previously exist. Once granted, your De Novo decision becomes a predicate for future 510(k) submissions from you and your competitors. That is both a strategic advantage and a responsibility to understand fully.

Too many startup founders either default to a 510(k) when no valid predicate exists—setting themselves up for a Not Substantially Equivalent (NSE) determination—or assume they need a PMA and never pursue clearance at all. The De Novo pathway exists precisely to bridge that gap, and underutilizing it is a costly mistake.

De Novo vs. 510(k) vs. PMA: Choosing the Right Lane

Before investing resources in any submission strategy, you need to classify your device correctly. Here is how the three primary pathways differ in practical terms:

• 510(k): Requires demonstration of substantial equivalence to a legally marketed predicate. Best for devices with established technology and a clear predicate chain. FDA review is typically 90 days for Standard, faster for Abbreviated.
• De Novo: Used when no valid predicate exists, but the device presents low-to-moderate risk. Results in a new Class I or Class II classification. FDA's target review time is 150 days under MDUFA V commitments.
• PMA: Required for Class III devices—those where general controls and special controls are insufficient to provide reasonable assurance of safety and effectiveness. Requires valid scientific evidence, typically including clinical trials. Review timelines extend to 180 days or longer.

The critical trigger for De Novo is the absence of a valid predicate. Under 21 CFR 807.100, if FDA issues an NSE decision in response to a 510(k), the sponsor may submit a De Novo request within 30 days of that determination. Alternatively, sponsors can submit a De Novo request directly—without first filing a 510(k)—when the novel nature of the device is already apparent.

When De Novo Is the Right Strategic Choice

The De Novo pathway is appropriate when all of the following conditions are met:

• Your device is new to the U.S. market with no legally marketed predicate under 21 CFR 807.92
• The device technology or intended use creates a new type of risk profile not currently classified by FDA
• Risk is low-to-moderate and can be mitigated through general controls alone (Class I) or general and special controls (Class II)
• You have—or can generate—performance data sufficient to establish special controls for your new classification

Common De Novo candidates include first-of-kind software as a medical device (SaMD) products, novel diagnostic algorithms, combination-technology devices, and hardware with unique indications that fall outside existing classification panels. FDA's guidance document De Novo Classification Process (Evaluation of Automatic Class III Designation), updated in 2021, remains the primary reference document for understanding submission requirements.

How to Build a De Novo Submission That Succeeds

A De Novo request is not simply a 510(k) without a predicate. It requires a fundamentally different evidentiary structure. Here is what FDA expects:

• Device Description: A thorough technical description that clearly articulates what the device does, how it works, and why it is novel. Ambiguity here triggers Additional Information (AI) requests immediately.
• Risk-Based Classification Rationale: You must affirmatively argue why Class II is appropriate—not just assert it. FDA evaluates probable risks and benefits. Reference FDA's guidance on factors to consider when making benefit-risk determinations.
• Proposed Special Controls: This is where many sponsors underinvest. Special controls are the regulatory conditions that will mitigate risk for your device type and all future devices in that classification. They must be specific, enforceable, and technically grounded. Vague special controls will slow your review.
• Performance Data: Bench testing, usability studies, biocompatibility data under ISO 10993, software documentation under IEC 62304 where applicable, and clinical data if risk warrants it. Align your test protocols with recognized FDA consensus standards where possible—use of recognized standards under 21 CFR 820 and FDA's Standards Database simplifies the evidentiary burden.
• Labeling: Draft labeling must reflect the intended use and indications you are seeking. Inconsistencies between labeling and your device description are a common source of AI requests.

Common Pitfalls to Avoid

After reviewing hundreds of regulatory submissions, the failure patterns are consistent. Sponsors underestimate the depth of the special controls section, submit performance data that is not representative of the final device design, or fail to engage FDA through Pre-Submission (Q-Sub) meetings before filing. A Pre-Sub meeting—available under FDA's guidance on the Q-Sub program—is not optional for a De Novo. It is the single highest-leverage activity you can do before committing to a full submission. FDA will tell you whether your classification rationale holds, whether your performance testing is adequate, and whether you are targeting the right pathway.

Missing this step costs sponsors an average of six to twelve months in back-and-forth AI cycles—delays that are entirely avoidable.

The Bottom Line

The De Novo pathway is one of FDA's most powerful—and most misunderstood—regulatory tools. When applied correctly, it clears a first-in-class device, establishes the regulatory framework for an entire product category, and creates a durable market advantage. When approached without preparation, it produces AI requests, extended timelines, and erosion of investor confidence.

At ADB Consulting & CRO Inc., we help medical device companies navigate De Novo strategy from pre-submission through classification order—building submissions that are technically rigorous, strategically sound, and reviewer-ready.

If you are developing a novel device and are unsure whether De Novo is the right pathway, do not guess. Book a free discovery call with Andre Butler and get a clear regulatory roadmap tailored to your device and your timeline. Visit adbccro.com to schedule your call today.

Your Device Is Innovative. That Is Exactly the Problem.

You have built something genuinely new. Your device does not fit neatly into an existing FDA product code, and there is no legally marketed predicate you can point to for a 510(k) submission. Congratulations — and also, welcome to one of the most misunderstood regulatory pathways in the FDA toolkit: the De Novo classification request.

For medical device startups and small-to-mid-size companies developing novel, low-to-moderate risk technologies, the De Novo pathway is not a consolation prize. When used strategically, it is a powerful route to market that simultaneously establishes your device as a predicate for future 510(k) submitters. But it requires a fundamentally different mindset than a standard 510(k), and underestimating its complexity is a mistake that costs companies months and significant capital.

What De Novo Actually Is — and Is Not

Established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act and further codified through the 21st Century Cures Act, the De Novo process allows FDA to create a new device classification for novel devices that are low to moderate risk but lack a predicate. It is not a PMA lite. It is not a shortcut. It is a classification mechanism that, if granted, places your device into Class I or Class II with special controls that FDA defines — often with your direct input.

Per 21 CFR Part 860, Subpart D, a De Novo request can be submitted in one of two ways: following a Not Substantially Equivalent (NSE) determination after a 510(k) submission, or directly without first submitting a 510(k). Since 2017, the direct De Novo pathway has become increasingly common and is generally preferred for devices where predicate absence is obvious from the outset.

When De Novo Is the Right Call

The decision to pursue De Novo should be deliberate, not default. Ask these questions before committing to the pathway:

• Is your device Class III by default? Under 21 CFR 860.3, any device that cannot be classified into Class I or II through 510(k) is automatically Class III — requiring PMA. De Novo is the mechanism to reclassify it downward if the risk profile supports it.
• Can general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness? This is the statutory standard. If your device genuinely requires clinical evidence typical of a PMA, De Novo may not be appropriate.
• Does your device fall into an existing product code with a different intended use? Sometimes what appears to be a De Novo situation is actually a 510(k) with a well-scoped intended use statement. This distinction matters enormously.
• Are you prepared to help FDA draft special controls? This is one of the most underappreciated aspects of De Novo. The special controls that emerge from your request will govern not just your device, but every future 510(k) predicated on it.

Building a De Novo Request That Does Not Get Rejected

FDA's acceptance rate for De Novo requests has improved, but substantive deficiencies remain common. The most frequent issues we see at ADB Consulting and CRO Inc. involve three areas: risk classification justification, special controls development, and the performance testing package.

Risk Classification Justification

Your De Novo request must convincingly argue that your device belongs in Class I or Class II. This means a thorough benefit-risk analysis grounded in FDA's guidance document 'De Novo Classification Process (Evaluation of Automatic Class III Designation),' finalized in 2021. Reference the factors outlined in 21 CFR 860.7 and align your narrative to FDA's own framework. Generalities will not hold up to review.

Proposed Special Controls

This section separates experienced regulatory teams from inexperienced ones. You are essentially proposing the regulatory controls that will define your device type going forward. Special controls typically include design requirements, performance testing standards, biocompatibility per ISO 10993, labeling requirements, and post-market surveillance obligations. Draft them specifically enough to be enforceable, but not so narrowly that they prevent you from iterating your own product.

Performance Testing Package

Bench testing, biocompatibility, software documentation (per IEC 62304 if applicable), electrical safety, and — where indicated — clinical data must be scoped to your device's risk profile. FDA's review clock under MDUFA IV targets 150 days for De Novo requests, but a deficient package will restart that clock.

Q-Submission First. Always.

Before submitting a De Novo request, engage FDA through the Q-Submission (Pre-Sub) program. This is not optional for complex devices. A well-constructed Pre-Sub meeting allows you to align on the classification rationale, confirm the testing FDA expects, and surface objections before they become a Refuse to Accept or a deficiency letter. Skipping this step is one of the most expensive shortcuts a company can take.

The Strategic Value Most Companies Miss

A granted De Novo does more than clear your device for market. It creates a new product code and establishes your device as a Class II predicate. If your commercial strategy includes platform expansion, this has long-term competitive and portfolio implications worth planning for from day one — not after clearance.

Ready to Determine the Right Pathway for Your Device?

At ADB Consulting and CRO Inc., Andre Butler and the team work directly with startup founders, VP-level regulatory affairs leaders, and quality executives to assess pathway feasibility, structure submissions, and guide devices through FDA review with precision. Whether you are at ideation or staring down an NSE determination, we can help you move forward with clarity.

Book your free discovery call today at adbccro.com and get a candid, expert assessment of your regulatory situation — no fluff, no generic advice, just a clear path forward.

Your Device Is Novel. Now What?

You have built something genuinely new. It does not fit neatly into an existing FDA classification, and a thorough predicate search has turned up nothing close enough to support a 510(k). For many medical device founders, this moment triggers panic. It should not. What it should trigger is a serious, strategic conversation about the De Novo classification pathway.

De Novo is not a consolation prize for devices that could not find a predicate. It is a legitimate, well-defined regulatory route established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act, and for the right device, it is exactly the right tool. Understanding when and how to use it is what separates founders who move efficiently toward market clearance from those who spend years stuck in regulatory limbo.

What De Novo Actually Is -- and Is Not

The De Novo process allows FDA to classify a novel, low-to-moderate risk device as Class I or Class II when no legally marketed predicate exists. A successful De Novo request results in a new device classification, complete with a product code, classification regulation, and -- critically -- special controls that define the risk mitigation requirements for that device type. Once granted, the De Novo order itself becomes a predicate that future manufacturers can reference in their own 510(k) submissions.

This is not a PMA. You are not submitting clinical data to prove safety and effectiveness under a burden-of-proof standard reserved for Class III devices. But De Novo is also not a streamlined 510(k). The evidentiary expectations are more rigorous, the review timelines are longer, and the strategic preparation required is substantially more involved. Treating it casually is one of the most expensive mistakes a startup can make.

When De Novo Is the Right Pathway

There are two routes into De Novo under 21 CFR Part 860, Subpart D. The first is a direct De Novo request submitted without a prior 510(k). The second follows an FDA Not Substantially Equivalent (NSE) determination -- commonly called a 'refuse to file' or 'not se' decision -- on a 510(k) submission. FDA's guidance document, 'De Novo Classification Process (Evaluation of Automatic Class III Designation),' finalized in 2021, provides the authoritative procedural framework and is essential reading for any regulatory team preparing a submission.

De Novo is appropriate when all of the following are true:

• The device is novel with no legally marketed predicate under 21 CFR 807.92(a)(3)
• The device presents low-to-moderate risk such that general and special controls are sufficient to provide reasonable assurance of safety and effectiveness
• The intended use and technological characteristics are well-defined and can support a coherent special controls framework

If your device is high-risk or if general and special controls cannot mitigate the identified risks, De Novo is not available to you. PMA becomes the required pathway under Section 515 of the FD&C Act.

What Goes Into a De Novo Request

A well-constructed De Novo request is not simply a 510(k) with the predicate section removed. It requires a fundamentally different architecture. Your submission must include:

• Device description and intended use: Precise, unambiguous, and defensible under FDA scrutiny
• Risk-based classification rationale: A thorough demonstration that Class II is appropriate, supported by a risk analysis grounded in ISO 14971
• Proposed special controls: This is where most submissions succeed or fail. You must propose the specific controls -- performance testing, labeling requirements, postmarket surveillance, clinical data, or combinations thereof -- that mitigate each identified risk
• Performance testing data: Bench testing, biocompatibility per ISO 10993, software documentation under FDA's software guidance framework if applicable, and any clinical evidence necessary to support your special controls rationale
• Labeling: Compliant with 21 CFR Part 801 and aligned with your proposed intended use

FDA's current statutory review goal for De Novo requests is 150 days under MDUFA V commitments, though complex submissions often require additional information requests that extend that timeline. Building a realistic project plan from day one -- one that accounts for FDA interaction, potential Additional Information (AI) letters, and internal resource constraints -- is not optional. It is foundational.

The Strategic Value Most Companies Overlook

Beyond market access, a granted De Novo order creates durable competitive value. Your device becomes the predicate. Competitors who want to enter your space using 510(k) must now reference your classification order and demonstrate substantial equivalence to your device. You have, in effect, defined the regulatory standard for your device category. For investors, that is a significant differentiator worth communicating clearly in your fundraising narrative.

Common Pitfalls That Derail De Novo Submissions

• Proposing special controls that are too vague for FDA to enforce or verify
• Underestimating the clinical or performance data needed to support the proposed controls
• Submitting without a pre-submission (Q-Sub) meeting to align with FDA on the classification rationale before filing
• Conflating 'novel' with 'high-risk' and failing to build a credible Class II argument
• Inadequate software documentation for devices with software functions, particularly those subject to FDA's 2023 guidance on predetermined change control plans

Start With a Pre-Submission Meeting

If you take one piece of advice from this article, let it be this: request a Pre-Submission (Q-Sub) meeting with FDA before you prepare your De Novo package. Under 21 CFR Part 812 and FDA's Q-Sub guidance, you can get written FDA feedback on your proposed classification rationale, special controls framework, and testing requirements. This interaction does not supports outcomes, but it dramatically reduces the risk of avoidable deficiencies and can save months of rework.

At ADB Consulting and CRO Inc., we have guided medical device companies through De Novo strategy from initial pathway analysis through FDA response management. If your device is novel and you are trying to determine whether De Novo is the right move -- or how to build a submission that holds up -- we are here to help.

Book a free discovery call with Andre Butler and the ADB Consulting team at adbccro.com. Bring your device concept, your predicate search results, and your questions. We will give you a straight answer on where you stand and what it takes to move forward.

When Your Device Does Not Fit the Mold: Understanding the De Novo Pathway

You have built something genuinely new. Your device does not look like anything already on the market, and no legally marketed predicate exists to support a 510(k) submission. For many medical device founders, that realization triggers a moment of panic. It should not. The FDA De Novo classification request process exists precisely for this situation, and when executed correctly, it is a legitimate and strategic route to market for novel, low-to-moderate risk devices.

This post breaks down what the De Novo pathway actually involves, who it is right for, and what it takes to build a submission that earns a favorable classification order from FDA.

What Is a De Novo Classification Request?

The De Novo process is authorized under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and is codified in 21 CFR Part 860, Subpart D. It allows a device sponsor to request that FDA classify a novel device into Class I or Class II, establishing new special controls specific to that device type.

Before the pathway was modernized by the 21st Century Cures Act in 2016, sponsors had to first receive a Not Substantially Equivalent (NSE) determination from a 510(k) before pursuing De Novo. Today, under 21 CFR 860.257, you can submit a De Novo request directly to FDA without going through 510(k) first. This direct route saves significant time and eliminates the cost of a failed 510(k).

If FDA grants your De Novo request, three important things happen:

• Your device is classified into Class I or Class II with device-specific special controls
• Your device becomes an established predicate for future 510(k) submitters in that device category
• FDA publishes a classification regulation that benefits the entire industry

That third point is underappreciated. A successful De Novo does not just get your device cleared. It shapes the regulatory landscape for the device type you created.

Is De Novo Right for Your Device?

De Novo is appropriate when your device presents a novel technology or intended use that poses low to moderate risk, but general controls alone are insufficient to provide reasonable assurance of safety and effectiveness. If your device clearly poses high risk, you are looking at a PMA under 21 CFR Part 814, not De Novo.

Common scenarios where De Novo is the right call include:

• A software-based diagnostic tool with no cleared predicate in your specific intended use population
• A novel combination of existing technologies that creates a meaningfully different risk profile
• A device with a new physiological measurement modality that FDA has not classified before
• An AI/ML-driven device where predicate-based substantial equivalence arguments are untenable

If you have exhausted a predicate search and your best candidates have meaningful differences in intended use or technology that you cannot bridge, De Novo deserves serious consideration. The worst thing you can do is force a weak 510(k) with a distant predicate and invite a Not Substantially Equivalent determination months into your review.

What Goes Into a De Novo Submission?

FDA's definitive guidance on this is the October 2021 document titled 'De Novo Classification Process (Evaluation of Automatic Class III Designation).' Your submission should be built around the core elements FDA expects to evaluate.

Device Description and Indications for Use

These must be precise. FDA will use your indications statement to draft the classification regulation if your request is granted. Vague or overly broad indications create problems during review and can narrow your cleared indication in ways you did not anticipate.

Risk Analysis and Risk-Benefit Assessment

You need a rigorous risk analysis, typically structured per ISO 14971:2019, that identifies hazards, estimates risk, and explains why residual risks are acceptable given the device's benefits. FDA reviewers use your risk analysis to evaluate whether Class II controls are sufficient or whether Class III with PMA would be more appropriate.

Proposed Special Controls

This is where many sponsors underinvest. You must propose specific special controls that, together with general controls under 21 CFR Part 820 and your indications for use, provide reasonable assurance of safety and effectiveness. Special controls typically include performance standards, postmarket surveillance requirements, labeling requirements, and specific testing requirements. FDA may modify your proposed controls, but submitting well-reasoned proposals signals regulatory sophistication and shortens the negotiation cycle.

Performance Data

Bench testing, biocompatibility per ISO 10993, software documentation per FDA's Software guidance, clinical data if applicable, and any cybersecurity documentation under FDA's 2023 cybersecurity guidance should all be addressed based on your device type and risk profile.

Timeline and Practical Expectations

FDA's target total time for De Novo review under MDUFA V is 150 days from acceptance. However, acceptance review alone takes up to 15 days, and FDA frequently issues Additional Information (AI) requests during substantive review that pause the clock and extend real-world timelines. Plan for 12 to 18 months from submission to decision in most cases, particularly for novel device types that require significant internal FDA deliberation.

Strategic Advantages Beyond Market Clearance

Do not overlook the business value of being the De Novo holder. Competitors who want to market a substantially equivalent device must reference your device as their predicate in a 510(k). That positions your cleared device as the gold standard for the device type and creates a durable first-mover regulatory advantage. Investors and acquirers understand this. A De Novo classification order is a meaningful asset on your regulatory dossier.

Do Not Navigate This Alone

De Novo submissions demand deep regulatory strategy, precise technical writing, and a thorough understanding of how FDA classifies risk. A misstep in your proposed special controls or an underpowered risk-benefit analysis can result in a denial or a request to submit a PMA instead, which costs you years and millions of dollars.

At ADB Consulting and CRO Inc., Andre Butler and the team have helped medical device companies across therapeutic areas structure and execute De Novo submissions that align with FDA expectations from the first interaction. We understand what FDA is looking for because we have been in these conversations, and we build submissions that get devices classified and on the market.

If you are developing a novel device and are unsure whether De Novo is your path, book a free discovery call with our team. We will assess your device, your predicate landscape, and your timeline to give you a clear-eyed regulatory strategy on day one.

Visit adbccro.com to schedule your complimentary consultation today.